Study: vitamin E supps may increase lung cancer risk, especially in smokers

10 March 2008

Data from a new large-scale study of vitamin supplementation has revealed that such products do not protect against lung cancer and may even increase the risk of developing the disease. The findings, which are published in the American Thoracic Society's journal of Respiratory and Critical Care Medicine, suggest that the perceived wisdom that vitamin supplements provide a balanced diet and are an aid to longevity may be incorrect.

The VITAL study, which was conducted by Christopher Slatore and colleagues at the University of Washington in Seattle, USA, involved the analysis of data from more than 77,000 individuals aged between 50 and 76, who had been identified by the Seattle-Puget Sound SEER cancer registry. Subjects' lifestyle habits, including vitamin usage, smoking and medical characteristics were examined with respect to the rates of lung cancer.

Supplements not linked to cancer reduction

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight